Will a deal finally materialize?
Is MannKind's small share price tempting you to buy? Use this simple mental test to evaluate your decision.
After years of a failing strategy, AMD is finally narrowing its focus.
Regeneron topped estimates Thursday as Eylea sales continue to soar. But the stock failed to hold its gains, as all eyes appear to now be on the biotech's pipeline.
A look at five component suppliers that won spots inside of the newly released Apple Watch.
Here are 3 things investors should know about the Apple Watch’s innards.
Which beaten down chipmaker is a better contrarian buy?
The generic-drug market is sizzling hot. Here are three investing ideas to catch some of that heat wave.
These three companies have the potential to double their share price from current levels. Here's why.
Why doesn’t the U.S. government want Intel to sell supercomputer chips to China?